Biblio
Export 624 results:
Author [ Title
Filters: Keyword is Alzheimer Disease [Clear All Filters]
“Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.”, J Alzheimers Dis, vol. 97, no. 2, pp. 567-572, 2024.
, “A Super-Resolved View of the Alzheimer's Disease-Related Amyloidogenic Pathway in Hippocampal Neurons.”, J Alzheimers Dis, vol. 83, no. 2, pp. 833-852, 2021.
, “A systematic review of lifestyle-based interventions for managing Alzheimer's disease: Insights from randomized controlled trials.”, J Alzheimers Dis, vol. 102, no. 4, pp. 943-966, 2024.
, “T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 123-38, 2016.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “Targeting Caspases 3/6 and Cathepsins L/B May Decrease Laminopathy-Induced Apoptosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. 1, pp. 211-221, 2024.
, “Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.
, “Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis.”, J Alzheimers Dis, vol. 51, no. 3, pp. 671-5, 2016.
, “Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 509-513, 2018.
, “Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.”, J Alzheimers Dis, vol. 101, no. s1, pp. S129-S140, 2024.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “A TgCRND8 Mouse Model of Alzheimer's Disease Exhibits Sexual Dimorphisms in Behavioral Indices of Cognitive Reserve.”, J Alzheimers Dis, vol. 51, no. 3, pp. 757-73, 2016.
, “Three-Dimensional Eigenbrain for the Detection of Subjects and Brain Regions Related with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1163-79, 2016.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges.”, J Alzheimers Dis, vol. 49, no. 3, pp. 617-31, 2016.
, “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “Transcriptomic Profiling Reveals Neuroinflammation in the Corpus Callosum of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1421-1433, 2024.
, “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
, “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “Trends, Predictors, and Outcomes of Healthcare Resources Used in Patients Hospitalized with Alzheimer's Disease with at Least One Procedure: The Nationwide Inpatient Sample.”, J Alzheimers Dis, vol. 57, no. 3, pp. 813-824, 2017.
, “tRNA-Derived Fragments in Alzheimer's Disease: Implications for New Disease Biomarkers and Neuropathological Mechanisms.”, J Alzheimers Dis, vol. 79, no. 2, pp. 793-806, 2021.
, “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Ubisol-Q10 (a Nanomicellar Water-Soluble Formulation of CoQ10) Treatment Inhibits Alzheimer-Type Behavioral and Pathological Symptoms in a Double Transgenic Mouse (TgAPEswe, PSEN1dE9) Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 221-236, 2018.
,